Skip to main content

Beckman Coulter Posts Rise in Q2 Sales

NEW YORK, July 26 (GenomeWeb News) - Beckman Coulter reported today a roughly eight percent rise in second-quarter sales, driven in part by growth in the company's clinical diagnostics and biomedical research divisions.


Beckman Coulter's sales for the period were $597.3 million, up from $551.8 million in the second quarter 2003. Sales in the company's clinical diagnostics division climbed 10 percent on strong sales of the UniCel Dxl 800 immunoassay system, while sales in its biomedical division were up four percent.


Beckman Coulter posted net earnings of $58.3 million in the second quarter, an almost 12 percent increased over the $52.2 million recorded in same period last year.


Looking ahead, the company said that it expects sales in the third quarter to rise between eight and 11 percent, and total year sales to be up nine to 10 percent.


The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.